8-K: CytomX Reports Q3 2025 Results, Advances Oncology Pipeline

CytomX Therapeutics announced its third quarter 2025 financial results and provided updates on its oncology pipeline, including progress for CX-2051 and CX-801.

Summary

• Q3 2025 total revenue was $6.0 million, a significant decrease from $33.4 million in Q3 2024, primarily due to the completion of Bristol Myers Squibb collaboration obligations and decreased Moderna activities.
• The company reported a net loss of $14.2 million for Q3 2025, compared to a net income of $5.7 million in Q3 2024.
• Cash, cash equivalents, and investments totaled $143.6 million as of September 30, 2025, with an expected cash runway extending to the second quarter of 2027.
• CX-2051 Phase 1 dose expansion enrollment is robust, and a data update is on track for Q1 2026.
• A Phase 1b CX-2051 combination study with bevacizumab in colorectal cancer (CRC) is expected to commence in Q1 2026.
• Positive CX-801 Phase 1 monotherapy biomarker data in advanced melanoma will be presented at SITC 2025, supporting its ongoing combination study with KEYTRUDA (pembrolizumab).
• Initial clinical data for CX-801 in combination with KEYTRUDA in advanced melanoma is anticipated in 2026.
• Rachael Lester, MBA, was appointed Senior Vice President, Chief Business Officer in October 2025.

Sentiment

Score: 5

Explanation: Mixed results. While the financial performance shows a significant decline in revenue and a shift to net loss, the company maintains a solid cash runway and reports positive clinical and preclinical progress for its key pipeline assets, CX-2051 and CX-801, which are critical for future growth.

Positives

• CX-2051 Phase 1 dose expansion enrollment is robust across multiple dose levels, supporting a potential registrational study in advanced CRC.
• CX-2051 Phase 1 data update remains on track for Q1 2026, providing clarity on its development timeline.
• CX-801 monotherapy biomarker data in advanced melanoma patients supports its mechanism of action and the ongoing combination study with KEYTRUDA.
• CX-801 monotherapy has been well tolerated at doses exceeding the approved dose of unmasked IFN2b, indicating a favorable safety profile for the PROBODY platform.
• Gene expression analysis of preand post-treatment tumor biopsies demonstrated consistently increased expression of interferon-stimulated genes, confirming CX-801's biological activity.
• Patients showed evidence of T-cell and NK cell activation and upregulation of immune checkpoint genes (PD-1, PD-L1), suggesting potential synergy with checkpoint inhibitors.
• Evidence of sustained elevation of CXCL10 in the tumor but not the blood was observed, indicating preferential CX-801 activity in the tumor versus the periphery.
• PK analysis demonstrated dose-proportional exposure of CX-801, which remained predominantly in its intact (masked) form in circulation.
• Cash, cash equivalents and investments of $143.6 million provide an expected cash runway to Q2 2027, offering financial stability for pipeline advancement.
• Total operating expenses decreased by $7.6 million in Q3 2025 compared to Q3 2024, driven by reduced R&D and G&A expenses, reflecting cost management.
• Preclinical data for CX-908, a dually masked PROBODY T-cell Engager, showed potent tumor regressions and a 100-fold improvement in tolerability, including significantly reduced cytokine release vs. an unmasked molecule.

Negatives

• Total revenue for Q3 2025 significantly decreased to $6.0 million from $33.4 million in Q3 2024, primarily due to the completion of Bristol Myers Squibb collaboration obligations and reduced Moderna activities.
• The company reported a net loss of $14.2 million in Q3 2025, a reversal from the net income of $5.7 million in Q3 2024.
• Cash, cash equivalents and investments decreased to $143.6 million as of September 30, 2025, from $158.1 million as of June 30, 2025.

Risks

• Forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause actual results, performance, or achievements to be materially different.
• The unproven nature of CytomX's novel PROBODY therapeutic technology presents inherent development risks.
• Uncertainties exist regarding the company's ability to raise sufficient funds to carry out its planned research and development activities.
• Clinical trial product candidates are in initial stages of clinical development, and other product candidates are in preclinical development, with a long and uncertain path to potential approval.
• Results of preclinical research and early clinical trials, including initial CX-2051 and CX-801 results, may not be predictive of future results.
• There is a possibility that clinical trials will not be successful.
• Current preclinical research may not result in additional product candidates.
• The company's dependence on the success of CX-2051 and CX-801 introduces concentration risk.
• Reliance on third parties for the manufacture of product candidates poses supply chain and quality control risks.
• Possible regulatory developments in the United States and foreign countries could impact product development and approval timelines.
• The risk of incurring higher costs than expected for research and development or unexpected costs and expenses could negatively affect financial performance.

Future Outlook

CytomX is on track for a CX-2051 Phase 1 data update in Q1 2026 and plans to initiate a Phase 1b combination study with bevacizumab in CRC in Q1 2026 to inform potential late-phase development. The company aims to advance CX-2051 towards a potential registrational study in advanced, late-line CRC and explore its potential in earlier lines of CRC therapy and other EpCAM positive cancers. Initial clinical data for CX-801 in combination with KEYTRUDA in advanced melanoma is anticipated in 2026.

Management Comments

• "CytomX continued to execute against its pipeline priorities this quarter, highlighted by robust Phase 1 expansion enrollment for CX-2051. We remain on track for a CX-2051 Phase 1 data update in Q1 2026." Sean McCarthy, D.Phil., chief executive officer and chairman of CytomX.
• "Looking ahead to 2026, CX-2051 is well positioned as a first-in-class EpCAM-directed, topoisomerase-1 ADC designed to address the high unmet need in CRC and a wide range of other EpCAM-expressing indications. CytomXs top priority is to advance CX-2051 towards a potential registrational study in advanced, late-line CRC." Sean McCarthy, D.Phil., chief executive officer and chairman of CytomX.
• "We are also pleased with the dose escalation progress for our PROBODY interferon alpha-2b, CX-801, and look forward to presenting encouraging initial biomarker data at SITC which underscore this potent masked cytokines therapeutic potential in combination with checkpoint inhibitors in advanced melanoma." Sean McCarthy, D.Phil., chief executive officer and chairman of CytomX.

Industry Context

CytomX operates in the highly competitive oncology biopharmaceutical sector, focusing on conditionally activated biologics. Their PROBODY platform aims to improve the therapeutic index of ADCs, T-cell engagers, and immune modulators by localizing activity to the tumor microenvironment. The development of CX-2051 (EpCAM ADC) and CX-801 (PROBODY Interferon alpha-2b) addresses significant unmet needs in colorectal cancer and melanoma, respectively, areas with intense research and development activity from numerous pharmaceutical companies. The collaboration with major players like Bristol Myers Squibb, Amgen, Astellas, Regeneron, and Moderna indicates a recognized potential for their platform technology within the broader industry.

Comparison to Industry Standards

• CX-2051, as a first-in-class EpCAM-directed, topoisomerase-1 ADC, targets a high unmet need in CRC, potentially offering a differentiated approach compared to existing or pipeline ADCs that may target other antigens or use different payloads.
• CX-801's preclinical data showing 100-fold improvement in tolerability and significantly reduced cytokine release compared to an unmasked CDH3xCD3 molecule (CX-908) highlights the potential of the PROBODY platform to overcome systemic toxicity issues common with potent cytokines and T-cell engagers, a key challenge in the development of such therapies across the industry.
• The ability of CX-801 to induce T-cell and NK cell activation and upregulate immune checkpoint genes, including PD-1 and PD-L1, suggests a mechanism that could synergize with existing checkpoint inhibitors like KEYTRUDA, a standard of care in melanoma, potentially expanding treatment options for patients.

Management Changes

Stakeholder Impact

• Shareholders: Negative impact from decreased revenue and net loss, but positive sentiment from pipeline progress and extended cash runway. Potential for future value creation if clinical programs succeed.
• Employees: Potential positive impact from continued pipeline advancement and strategic appointments, suggesting stability and future growth opportunities.
• Customers (Patients): Potential positive impact from the continued development of novel cancer therapies (CX-2051, CX-801, CX-908) addressing high unmet medical needs.
• Collaborators (Bristol Myers Squibb, Amgen, Astellas, Regeneron, Moderna): Continued collaboration on research programs, though revenue from BMS and Moderna decreased.

Next Steps

• CX-2051 Phase 1 data update in Q1 2026.
• Start of CX-2051 Phase 1b CRC combination study with bevacizumab in Q1 2026.
• Evaluation of multiple non-CRC, EpCAM-expressing tumor indications for potential future CX-2051 development.
• Presentation of CX-801 monotherapy biomarker data at SITC 2025.
• Anticipated initial clinical data for CX-801 in combination with KEYTRUDA in advanced melanoma in 2026.
• Advancing CX-2051 towards a potential registrational study in advanced, late-line CRC.
• Focused investments to further unlock the potential of CX-2051, including moving into earlier lines of CRC therapy and additional EpCAM positive cancers.

Key Dates

Recommendation

While the financial results for Q3 2025 show a significant decline in revenue and a net loss, reflecting the completion of certain collaboration milestones, the company has extended its cash runway to Q2 2027. More importantly, the pipeline updates for CX-2051 and CX-801 are largely positive, with key data readouts and study initiations anticipated in Q1 2026 and throughout 2026. The positive biomarker data for CX-801 and robust enrollment for CX-2051's expansion phase indicate clinical progress. Given the early-stage nature of these programs and the mixed financial performance, a "hold" recommendation is appropriate. Investors should await the upcoming clinical data to assess the potential for future value creation before making further investment decisions. The long cash runway provides a buffer for these developments.

Keywords

CytomX Therapeutics, CTMX, Q3 2025, financial results, oncology, biologics, PROBODY, CX-2051, EpCAM, ADC, colorectal cancer, CRC, CX-801, interferon alpha-2b, immunotherapy, melanoma, KEYTRUDA, clinical trials, biopharmaceutical, drug development, cancer treatment, SEC filing, 8-K